Akeso Inc
OTC:AKESF

Watchlist Manager
Akeso Inc Logo
Akeso Inc
OTC:AKESF
Watchlist
Price: 14.265 USD -4.58% Market Closed
Market Cap: $12.8B

Net Margin

-30.1%
Current
Declining
by 8.4%
vs 3-y average of -21.7%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-30.1%
=
Net Income
¥-846m
/
Revenue
¥2.5B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-30.1%
=
Net Income
$-846m
/
Revenue
¥2.5B

Peer Comparison

Country Company Market Cap Net
Margin
CN
Akeso Inc
HKEX:9926
104.7B HKD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
186.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
162.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.1B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...

Market Distribution

Lower than 88% of companies in China
Percentile
12th
Based on 8 721 companies
12th percentile
-30.1%
Low
-416 945.9% — -1.5%
Typical Range
-1.5% — 8.9%
High
8.9% — 17 382.1%
Distribution Statistics
China
Min -416 945.9%
30th Percentile -1.5%
Median 3.5%
70th Percentile 8.9%
Max 17 382.1%

Akeso Inc
Glance View

Market Cap
12.8B USD
Industry
Biotechnology

In the bustling landscape of biotechnology, Akeso Inc. emerges as a dynamic force addressing the dynamic and often daunting challenges of the medical world. Founded in 2012 and headquartered in China, this innovative company has made significant strides in the realm of biopharmaceuticals, particularly focusing on the research and development of novel therapies for oncology and immunology. Akeso Inc. differentiates itself through its comprehensive end-to-end approach, spanning discovery, clinical development, and commercialization. By leveraging its robust pipeline of therapeutic antibodies, the company constantly seeks to pioneer breakthroughs in cancer treatment and autoimmune disorders, thus driving its mission to enhance patient outcomes and address unmet medical needs. The economic engine of Akeso Inc. is driven by its ability to transform scientific research into viable therapeutic products. Revenue generation centers around the commercialization of their proprietary drugs, which often involves collaborations and strategic partnerships with major pharmaceutical players globally. These alliances not only expand the reach of Akeso's innovations but also provide essential capital and shared expertise that accelerate product advancement. The company's business model is further bolstered by licensing agreements and milestone payments, creating a steady stream of income as they navigate the rigorous pathways of drug approval and market entry. Through these ventures, Akeso Inc. not only secures its financial health but also continuously reinvests in its research endeavors, fueling a cycle of innovation that propels it forward in the competitive biotech arena.

AKESF Intrinsic Value
16.776 USD
Undervaluation 15%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-30.1%
=
Net Income
¥-846m
/
Revenue
¥2.5B
What is Akeso Inc's current Net Margin?

The current Net Margin for Akeso Inc is -30.1%, which is below its 3-year median of -21.7%.

How has Net Margin changed over time?

Over the last 3 years, Akeso Inc’s Net Margin has increased from -420.2% to -30.1%. During this period, it reached a low of -420.2% on May 30, 2022 and a high of 42.3% on Jun 30, 2023.

Back to Top